PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35550167-0	2022	Epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis synergizes the anticancer effects of sorafenib in hepatocellular carcinoma.	Sorafenib	91-100	metallothionein 1G	Homo sapiens	35-39	
35550167-4	2022	Herein, we report that sorafenib exerts its anticancer effects by activating metallothionein 1G (MT1G) expression.	Sorafenib	23-32	metallothionein 1G	Homo sapiens	77-95	
35550167-4	2022	Herein, we report that sorafenib exerts its anticancer effects by activating metallothionein 1G (MT1G) expression.	Sorafenib	23-32	metallothionein 1G	Homo sapiens	97-101	
35550167-6	2022	MT1G overexpression suppressed the cellular proliferation, migration, invasion, and tumour formation of HCC and sensitized cells to sorafenib treatment.	Sorafenib	132-141	metallothionein 1G	Homo sapiens	0-4	
35550167-7	2022	However, the disruption of MT1G attenuated the anticancer effects of sorafenib.	Sorafenib	69-78	metallothionein 1G	Homo sapiens	27-31	
35550167-8	2022	Mechanistically, sorafenib upregulated MT1G expression via hypomethylation of its promoter region by binding and inhibiting DNA methyltransferase 1 (DNMT1) and increasing its promoter accessibility in HCC cells.	Sorafenib	17-26	metallothionein 1G	Homo sapiens	39-43	
35550167-10	2022	Our collective data revealed that sorafenib exerts its anticancer effects through epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis in HCC and the activation of MT1G might constitute a strategy for enhancing the effect of sorafenib to suppress HCC cells.	Sorafenib	34-43	metallothionein 1G	Homo sapiens	117-121	
35550167-10	2022	Our collective data revealed that sorafenib exerts its anticancer effects through epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis in HCC and the activation of MT1G might constitute a strategy for enhancing the effect of sorafenib to suppress HCC cells.	Sorafenib	34-43	metallothionein 1G	Homo sapiens	165-169